GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Cyclically Adjusted Price-to-FCF

China Resources Pharmaceutical Group (HKSE:03320) Cyclically Adjusted Price-to-FCF : 5.62 (As of Jun. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Cyclically Adjusted Price-to-FCF?

As of today (2024-06-01), China Resources Pharmaceutical Group's current share price is HK$5.79. China Resources Pharmaceutical Group's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was HK$1.03. China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF for today is 5.62.

The historical rank and industry rank for China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

HKSE:03320' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 4.53   Med: 6.38   Max: 9.84
Current: 5.78

During the past 11 years, China Resources Pharmaceutical Group's highest Cyclically Adjusted Price-to-FCF was 9.84. The lowest was 4.53. And the median was 6.38.

HKSE:03320's Cyclically Adjusted Price-to-FCF is ranked better than
95.03% of 322 companies
in the Drug Manufacturers industry
Industry Median: 31.79 vs HKSE:03320: 5.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

China Resources Pharmaceutical Group's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was HK$2.162. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is HK$1.03 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


China Resources Pharmaceutical Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Cyclically Adjusted Price-to-FCF Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 7.77 4.99

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 7.77 - 4.99

Competitive Comparison of China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF falls into.



China Resources Pharmaceutical Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=5.79/1.03
=5.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, China Resources Pharmaceutical Group's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=2.162/117.2957*117.2957
=2.162

Current CPI (Dec23) = 117.2957.

China Resources Pharmaceutical Group Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.162 99.707 0.191
201512 0.586 102.015 0.674
201612 0.468 103.225 0.532
201712 0.450 104.984 0.503
201812 0.995 107.622 1.084
201912 0.970 110.700 1.028
202012 0.952 109.711 1.018
202112 1.545 112.349 1.613
202212 1.436 114.548 1.470
202312 2.162 117.296 2.162

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


China Resources Pharmaceutical Group  (HKSE:03320) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


China Resources Pharmaceutical Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines